Who is sponsoring NCT03556566?

NCT03556566 is sponsored by Immunitor LLC.

What drugs are being tested in NCT03556566?

Interventions in NCT03556566: Tableted vaccine (V3-OVA) containing ovarian cancer antigens.

What condition does NCT03556566 study?

NCT03556566 studies Ovarian Cancer.

Is NCT03556566 still recruiting?

NCT03556566 is currently status unknown. Last updated 30 August 2019.

Last reviewed 2019-08-30 · How we verify

NCT03556566: V3-OVA

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Open Label Immunotherapy Trial for Ovarian Cancer

Status unknown Phase 2 Last updated 30 August 2019

What this trial tests

Phase 2 trial testing Tableted vaccine (V3-OVA) containing ovarian cancer antigens in Ovarian Cancer in 20 participants. Status unknown.

Timeline

1 July 2018

Primary endpoint
30 November 2019

31 December 2019

Quick facts

Lead sponsor	Immunitor LLC
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	20
Start date	1 July 2018
Primary completion	30 November 2019
Estimated completion	31 December 2019
Sites	1 location across Mongolia

Drugs / interventions tested

Tableted vaccine (V3-OVA) containing ovarian cancer antigens — full drug profile →

Conditions studied

Ovarian Cancer — all drugs for Ovarian Cancer →

Sponsor

Immunitor LLC — full company profile →

Who can join

Adults 18 to 65, female only, with Ovarian Cancer. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This Phase II will evaluate a new type of ovarian cancer immunotherapy based on a fundamentally new approach that has been successfully tested in a published clinical study of liver cancer. We will test new tableted preparation, V3-OVA, obtained from hydrolyzed, inactivated blood and tumors of patients with cancer of ovaries. Study will last 3 months, 20 patients will be recruited, given one pill per day for three months. The primary clinical endpoint is effect on tumor size and burden after 3 months. Secondary endpoint will be effect on levels of tumor markers on monthly basis compared to baseline.

Publications & conference data

5 peer-reviewed publications reference this trial (live from Europe PMC):

Immunotherapy for Ovarian Cancer: Adjuvant, Combination, and Neoadjuvant.
Yang C, Xia BR, Zhang ZC, Zhang YJ, et al · · 2020 · cited 246× · PMID 33123161 · DOI 10.3389/fimmu.2020.577869
The role of caspase-8 in the tumor microenvironment of ovarian cancer.
Kostova I, Mandal R, Becker S, Strebhardt K. · · 2021 · cited 40× · PMID 33026575 · DOI 10.1007/s10555-020-09935-1
Development of Therapeutic Vaccines for Ovarian Cancer.
Chow S, Berek JS, Dorigo O. · · 2020 · cited 28× · PMID 33167428 · DOI 10.3390/vaccines8040657
Limitations and potential of immunotherapy in ovarian cancer.
Kumar S, Acharya S, Karthikeyan M, Biswas P, et al · · 2023 · cited 11× · PMID 38264664 · DOI 10.3389/fimmu.2023.1292166
Integrating Cancer Vaccines in the Standard-of-Care of Ovarian Cancer: Translating Preclinical Models to Human.
Chiang CL, Rovelli R, Sarivalasis A, Kandalaft LE. · · 2021 · cited 8× · PMID 34572778 · DOI 10.3390/cancers13184553

Verify or expand the search:

Other recruiting trials for Ovarian Cancer

Currently open trials in the same condition.

NCT06412120 — Study Evaluating Safety, Tolerability, and Metabolism of Niraparib · Phase 4 · recruiting
NCT06930755 — Study of NMS-03305293 in Adult Patients With Relapsed Ovarian Cancer · Phase 1 · recruiting
NCT07318558 — A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021) · Phase 3 · recruiting
NCT07491081 — EARLY Study: Evaluating the Specificity and Feasibility of the EARLY Biomarker Panel for Ovarian Cancer Detection · NA · recruiting
NCT07410676 — EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors · Phase 1, PHASE2 · recruiting

Other Immunitor LLC trials

Trials by the same sponsor.

NCT04377243 — Immunotherapy of Chronic Kidney Failure · Phase 2 · unknown
NCT04380532 — Tableted COVID-19 Therapeutic Vaccine · Phase 1, PHASE2 · unknown
NCT03916757 — V-Boost Immunotherapy in Glioblastoma Multiforme Brain Cancer · Phase 2 · unknown
NCT03550755 — Immunotherapy of Cervical Cancer With V3-Cervix · Phase 2 · unknown
NCT03572361 — Open Label Immunotherapy Trial for Breast Cancer · Phase 2 · unknown

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03556566 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Immunitor LLC
Last refreshed: 30 August 2019

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03556566.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing